Filing Details

Accession Number:
0001012975-16-000938
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-01-28 17:07:39
Reporting Period:
2016-01-26
Filing Date:
2016-01-28
Accepted Time:
2016-01-28 17:07:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1361248 Tetralogic Pharmaceuticals Corp TLOG Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1166285 Michael Steinmetz C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1249153 Dennis Henner C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252522 Nicholas Galakatos C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252523 Robert Liptak C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252525 Kurt Wheeler C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431403 Nicholas Simon C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431437 Clarus Ventures Ii, Llc C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431439 Clarus Ventures Ii Gp, L.p. C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431443 Clarus Lifesciences Ii, L.p. C/O Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-01-26 69,425 $0.30 4,575,280 No 4 S Direct
Common Stock Disposition 2016-01-27 209,984 $0.27 4,365,296 No 4 S Direct
Common Stock Disposition 2016-01-28 32,521 $0.26 4,332,775 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $.30 to $.32 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  2. The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $.23 to $.30 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.